• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India.硫酸羟氯喹在印度医护人员中用于预防 2019 年冠状病毒病(COVID-19)的群体药代动力学。
J Clin Pharmacol. 2022 Nov;62(11):1403-1411. doi: 10.1002/jcph.2092. Epub 2022 Jun 30.
2
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.羟氯喹用于 COVID-19 传染病的化学预防(PROLIFIC)以预防一线医护人员感染 COVID-19:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4.
3
Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.医护人员血清调查为羟氯喹预防 SARS-CoV-2 感染的有效性提供了支持性证据。
J Epidemiol Glob Health. 2021 Sep;11(3):283-288. doi: 10.2991/jegh.k.210518.001. Epub 2021 May 23.
4
Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.羟氯喹在日本皮肤型或系统性红斑狼疮患者中的群体药代动力学
Ther Drug Monit. 2016 Apr;38(2):259-67. doi: 10.1097/FTD.0000000000000261.
5
Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.羟氯喹作为医护人员 2019 冠状病毒病(COVID-19)的暴露前预防:一项随机试验。
Clin Infect Dis. 2021 Jun 1;72(11):e835-e843. doi: 10.1093/cid/ciaa1571.
6
HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers.在 COVID-19 中,HCQ 预防并未显示出医护人员的 QTc 延长。
Indian Heart J. 2021 Jan-Feb;73(1):74-76. doi: 10.1016/j.ihj.2020.11.005. Epub 2020 Nov 10.
7
Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India.羟氯喹暴露前预防不能为医护人员提供针对 COVID-19 的保护:印度北部一家三级保健医院的横断面研究。
J Basic Clin Physiol Pharmacol. 2022 Jan 7;33(1):103-107. doi: 10.1515/jbcpp-2021-0221.
8
Hydroxychloroquine for SARS CoV2 Prophylaxis in Healthcare Workers - A Multicentric Cohort Study Assessing Effectiveness and Safety.羟氯喹用于医护人员预防 SARS-CoV-2-一项评估有效性和安全性的多中心队列研究。
J Assoc Physicians India. 2021 Jun;69(6):11-12.
9
Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.羟氯喹在医护人员 COVID-19 预防中的安全性。
Indian J Med Res. 2021;153(1 & 2):219-226. doi: 10.4103/ijmr.IJMR_2294_20.
10
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?为什么用羟氯喹进行暴露前预防是一种安全且合理的针对 SARS-CoV-2 感染的方法?
J Glob Antimicrob Resist. 2020 Sep;22:864-865. doi: 10.1016/j.jgar.2020.07.022. Epub 2020 Aug 7.

本文引用的文献

1
Hydroxychloroquine for SARS CoV2 Prophylaxis in Healthcare Workers - A Multicentric Cohort Study Assessing Effectiveness and Safety.羟氯喹用于医护人员预防 SARS-CoV-2-一项评估有效性和安全性的多中心队列研究。
J Assoc Physicians India. 2021 Jun;69(6):11-12.
2
Hydroxychloroquine as Prophylaxis for COVID-19: A Review.羟氯喹作为2019冠状病毒病的预防措施:一项综述
Front Pharmacol. 2020 Dec 3;11:605185. doi: 10.3389/fphar.2020.605185. eCollection 2020.
3
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.羟氯喹在新冠肺炎患者中的群体药代动力学:对剂量优化的启示。
Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):703-713. doi: 10.1007/s13318-020-00648-y.
4
Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.基于新冠肺炎患者特征的羟氯喹给药方案优化:文献综述与模拟分析
Xenobiotica. 2021 Feb;51(2):127-138. doi: 10.1080/00498254.2020.1824301. Epub 2020 Sep 30.
5
Drug repurposing approach to fight COVID-19.药物重定位方法抗击 COVID-19。
Pharmacol Rep. 2020 Dec;72(6):1479-1508. doi: 10.1007/s43440-020-00155-6. Epub 2020 Sep 5.
6
Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.模型指导下的 COVID-19 患者羟氯喹给药:近期经验教训、尚存不确定性和差距。
Br J Clin Pharmacol. 2021 Feb;87(2):674-682. doi: 10.1111/bcp.14436. Epub 2020 Jul 19.
7
Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology.羟氯喹用于治疗新型冠状病毒肺炎所引发的热潮给风湿病学带来了挑战。
Lancet Rheumatol. 2020 May;2(5):e257. doi: 10.1016/S2665-9913(20)30089-8. Epub 2020 Apr 1.
8
Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.寻找羟氯喹预防 COVID-19 的剂量:对有效性的迫切探索。
Clin Pharmacol Ther. 2020 Oct;108(4):766-769. doi: 10.1002/cpt.1874. Epub 2020 Jun 1.
9
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物,在体外可有效抑制严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
10
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.

硫酸羟氯喹在印度医护人员中用于预防 2019 年冠状病毒病(COVID-19)的群体药代动力学。

Population Pharmacokinetics of Hydroxychloroquine Sulfate in Healthcare Workers, Given for Prophylaxis Against Coronavirus Disease 2019 (COVID-19) in India.

机构信息

Department of Clinical Pharmacology, Seth, GS Medical College & KEM Hospital, Mumbai, India.

Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

J Clin Pharmacol. 2022 Nov;62(11):1403-1411. doi: 10.1002/jcph.2092. Epub 2022 Jun 30.

DOI:10.1002/jcph.2092
PMID:35656997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9347612/
Abstract

Healthcare workers (HCWs) and frontline workers were recommended hydroxychloroquine (HCQ) 400 mg twice a day on day 1, followed by 400 mg once weekly for the next 7 weeks, as prophylaxis against COVID-19. There was limited information on the population pharmacokinetics (popPK) of HCQ in an Indian setting when administered for prophylaxis against COVID-19, and hence this study was proposed. It was a multicentric prospective study conducted at 3 sites in India wherein HCWs who were already on HCQ prophylaxis, who were about to start prophylaxis or who had stopped the prophylaxis for any reason were enrolled. Each participant gave 2 to 6 blood samples at different time points and whole-blood HCQ concentrations were assayed using liquid chromatography with tandem mass spectrometry (LC MS/MS). popPK analysis was performed using PUMAS 1.1.0. A total of N = 338 blood samples from N = 121 participants were included in the popPK analysis. A 2-compartment structural model with linear elimination was able to explain the observed data. Body weight was found to be a significant covariate influencing drug clearance. The final model was assessed using goodness-of-fit plots, a visual predictive check and a bootstrap, all of which confirmed that the model was appropriate. Simulations based on the current regimen showed that trough values were below the half-maximal effective concentration (EC50) of 0.7 μmol against COVID-19. A new weight-based dosage regimen was proposed to maintain the trough concentration above the EC50 threshold.

摘要

医护人员(HCWs)和一线工作人员被建议在第 1 天每天服用羟氯喹(HCQ)400mg,分两次服用,然后在接下来的 7 周内每周服用 400mg,作为预防 COVID-19 的措施。在印度,当用于预防 COVID-19 时,关于 HCQ 的群体药代动力学(popPK)的信息有限,因此提出了这项研究。这是一项在印度三个地点进行的多中心前瞻性研究,其中已经接受 HCQ 预防治疗的 HCWs、即将开始预防治疗或因任何原因停止预防治疗的 HCWs 都被纳入研究。每个参与者在不同时间点采集 2 到 6 份血样,使用液相色谱-串联质谱法(LC-MS/MS)测定全血 HCQ 浓度。popPK 分析使用 PUMAS 1.1.0 进行。共纳入了来自 121 名参与者的 338 份血样进行 popPK 分析。一个具有线性消除的两室结构模型能够解释观察到的数据。体重被发现是影响药物清除率的重要协变量。使用拟合度图、可视化预测检查和自举法对最终模型进行评估,所有这些都证实了模型的适用性。基于当前方案的模拟表明,谷值浓度低于 COVID-19 的半最大有效浓度(EC50)0.7μmol。提出了一种新的基于体重的剂量方案,以维持谷值浓度高于 EC50 阈值。